Abstract
Background Little data exists to guide the treatment of persistent COVID-19 in immunocompromised patients. We have employed a unique protocol combining tixegavimab/cilgavimab, and short-term combination antivirals including remdesivir.
Methods A retrospective single-center analysis of persistent COVID-19 in immunocompromised patients. Response was assessed by symptom resolution, declining C-reactive protein (CRP) levels and increasing SARS-CoV-2-PCR cycle-threshold (Ct) values.
Results Fourteen patients were included, including 2 kidney transplant recipients, 11 with B-cell lymphoproliferative disease, treated with anti-CD20 or ibrutinib, and 1 with rheumatoid arthritis, treated with anti-CD20. Median Ct-value was 27 (interquartile range (IQR):24-32). All patients received tixegavimab/cilgavimab and a 5-day course of remdesivir. Eleven also received nirmaltrevir/ritonavir and one received molnupiravir. Median follow-up was 45 days (IQR:12-89). Eleven patients had complete responses including symptom resolution, decrease in CRP, and increase in Ct values (all with either a negative PCR or Ct value>30 on day 4-16). Three patients had a partial response with relapses requiring re-admission. One had died, and two responded to prolonged antiviral treatments.
Conclusions A combination of monoclonal antibodies with antivirals has led to complete resolution of persistent COVID-19 in most severely-immunocompromised patients. Controlled studies will further direct the treatment of these patients, while more effective antivirals are urgently needed.
Key points Some immunocompromised patients develop persistent symptomatic SARS-CoV-2 infection. Combination of monoclonal antibodies plus one or more antivirals cured 11/14 patients. Non-responders benefitted from prolonged combination antiviral treatment. Controlled trials are needed to find optimal treatment of persistent COVID-19.
Competing Interest Statement
TBN received honoraria and consultation fees from AstraZeneca, MSD, GSK, Medison.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board of Assuta Ashdod University Hospital gave ethical approval for this work (#AAA-22-113). Informed consent was waved due to the retrospective design.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
(tbrosh{at}gmail.com; talbros{at}assuta.co.il)
(nirm{at}assuta.co.il)
(danielles{at}assuta.co.il)
(yonataned{at}assuta.co.il)
(sharonbenba{at}assuta.co.il)
(yafitse{at}assuta.co.il)
(amosc{at}assuta.co.il)
(erezbare{at}assuta.co.il)
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
